RT Journal Article
SR Electronic
T1 Urokinase-type Plasminogen Activator and Plasminogen-activator-inhibitor Type 1 Predict Metastases in Good Prognosis Breast Cancer Patients
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1475
OP 1482
VO 29
IS 5
A1 PATRICIA DE CREMOUX
A1 LAURE GRANDIN
A1 VÉRONIQUE DIÉRAS
A1 ALEXIA SAVIGNONI
A1 ARMELLE DEGEORGES
A1 RÉMY SALMON
A1 MARC A. BOLLET
A1 FABIEN REYAL
A1 BRIGITTE SIGAL-ZAFRANI
A1 ANNE VINCENT-SALOMON
A1 XAVIER SASTRE-GARAU
A1 HENRI MAGDELÉNAT
A1 LAURENT MIGNOT
A1 ALAIN FOURQUET
A1 ON BEHALF OF THE BREAST CANCER STUDY GROUP OF THE INSTITUT CURIE
YR 2009
UL http://ar.iiarjournals.org/content/29/5/1475.abstract
AB This retrospective analysis was designed to confirm the predictive role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type I (PAI-1) in the outcome of early stage, node-negative breast cancer patients. Patients and Methods: Node-negative patients having not received adjuvant chemotherapy, and for whom frozen samples were available, were selected. Results: Among the 169 patients included, 56.8% presented with uPA >3 ng/mg of proteins and/or PAI-1 >14 ng/mg of proteins. The median follow-up was 73 months. Significant correlations were found between uPA and disease-free survival (p [univariate]=0.003; p [multivariate]=0.01), and between uPA, PAI-1, and uPA plus PAI-1 and distant relapses (p=0.002). No significant correlation was found between uPA/PAI-1 and the risk of locoregional recurrence. Conclusion: This study demonstrated that uPA and PAI-1 are useful predictors of distant metastases in a subset of early stage, node-negative breast cancer patients.